Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Making LDL Matter Again: Addressing Clinical, Patient, and Payer Barriers in ASCVD Management : Episode 7
Unintended Consequences of Metric Changes
Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
Now Viewing
EP: 7.Unintended Consequences of Metric Changes
EP: 8.Reinstating LDL-C Targets
EP: 9.International LDL Thresholds
EP: 10.Nonstatin Therapy Decisions
EP: 11.PCSK9 Inhibitor Underuse
EP: 12.Payer and Prior Authorization Barriers
EP: 13.Adherence and Persistence
EP: 14.Cumulative LDL-C Exposure
EP: 15.Economic Burden and Systemwide Strategies
Panelists discuss how replacing outcome-driven low-density lipoprotein (LDL) targets with process-based statin-use measures led to unintended negative consequences. Clinicians began meeting performance goals without necessarily improving patient outcomes.
They note that the lack of specific targets fostered complacency and variability in practice standards. Health systems measured success by statin prescription rates rather than LDL reduction or cardiovascular prevention.
Panelists conclude that quality measures must prioritize outcomes over process metrics to restore the focus on meaningful patient improvements.
Related Videos
Related Content
